$CMPX has been mentioned 5 times over the past 12 months by 2 distinct FinTwit voices, with the first mention appearing on 2025-08-13. Biotech-focused voices dominate discussion of Compass Therapeutics, with @jacobplieth contributing 4 mentions and @adamfeuerstein contributing 1 mention. The most recent mentions occurred in July 2026, with @jacobplieth referencing $CMPX alongside other biotech tickers in an Esmo26 context.

A significant discussion emerged in late April 2026 following $CMPX's clinical results announcement. @adamfeuerstein detailed receiving unconfirmed material information through an anonymous source claiming to be a Compass employee, noting that the purported tovecimig efficacy data proved false when official results were released. On the same day, @jacobplieth commented on the trial outcomes, stating that patient crossover affected the overall survival benefit.